Human trial
Primary evidence or regulator source
706 adults without diabetes, overweight/obesity
Reported findings. In a 26-week phase 2 randomized trial of 706 adults with overweight or obesity, without diabetes, estimated average weight loss ranged from 6.0% to 10.8% across weekly subcutaneous cagrilintide study groups, versus 3.0% with placebo. These figures assume treatment adherence; doses increased over up to six weeks. These are study results, not dosing advice.
Nonresponse. The abstract does not report the proportion who failed to reach a weight-loss threshold. Treatment discontinuation is not a nonresponse rate.
Harms. Gastrointestinal events affected 41%–63% of cagrilintide participants versus 32% with placebo; administration-site reactions were also frequent. Across all groups, 10% permanently stopped treatment, including 4% because of adverse events.
Limits. No transfer to other routes/formulations/indications; clinician review pending. The primary figures use an analysis assuming adherence. The abstract reports similar reductions when nonadherence was included, without numerical detail. Participants and investigators knew which active treatment was assigned; active versus placebo was masked. These monotherapy findings do not establish combination, other-route or commercial-preparation outcomes.
Preparation: Cagrilintide monotherapy Route: subcutaneous
Read original source ↗Editorial review 2026-10-12. Clinician review pending.